Skip to main content

Adverse drug reactions in elders: looking for flubs in all the wrong places

A great deal of energy – and money - has been spent on preventing adverse drug reactions in elders. Many of these efforts have had limited success. Taking the next step to limit the harmful impacts of adverse drug reactions (ADRs) requires a fresh approach, and should focus on monitoring adverse effects of drugs after they are prescribed rather than preventing problem drugs from being prescribed in the first place.


At first blush, this approach seems counter-intuitive – isn’t it better to prevent a problem rather than trying to catch it once it has already happened? Of course, the answer is yes, but primary prevention of ADRs is often difficult if not impossible. In large part, this is because most ADRs are not due to “bad” drugs, but are unfortunate complications of drugs that have a legitimate place in the therapeutic armamentarium. This was demonstrated in an important national study
that evaluated causes of adverse drug reactions in elders that led to emergency room visits. Less than 4% of these ADRs were attributable to drugs from the Beers criteria, a consensus list of drugs to avoid prescribing to elders. In contrast, almost one-third of all adverse events were due to warfarin and insulin, which each have clear appropriate uses in elders. In another landmark study, Gurwitz and colleagues found that more than half of preventable ADRs in community-dwelling elders were due to failures to appropriately monitor drugs, rather than errors at the time the drug was initially prescribed. For example, 36% of ADRs were caused by a clinician not obtaining follow-up lab tests or inquiring about drug-related side effects. Another 37% of ADRs were caused by a clinician obtaining this information but failing to make an appropriate intervention (e.g., the treating physician did not stop or lower the dose of a drug after receiving lab test results that showed drug toxicity).

A focus on monitoring isn’t perfect, since some elders are going to experience serious adverse events that cannot be reasonably anticipated or prevented. Nonetheless, there is still a lot that we can do to help older patients. Many potential ADRs can be identified before they cause clinical harm to a patient. For example, close home monitoring of blood glucose can identify patients at risk of hypoglycemic episodes before such an episode happens. Other ADRs can be identified and mitigated before they cause substantial harm (a process termed “amelioration” in the ADR literature). For example, early detection of muscle aches and elevated creatinine kinase levels in a patient taking a statin can allow a clinician to stop the drug before the symptoms progress to full-blown rhabdomyolysis.

These monitoring interventions are hardly rocket science, and often are done in clinical practice. However, the lack of systems to support monitoring programs such as these often lead to patients falling through the cracks. The energy and resources of patient safety and ADR prevention programs can be mobilized to help develop these systems. If we are really committed to reducing ADRs and promoting patient safety, targeted interventions to improve monitoring of high-risk medications and conditions are likely to yield greater benefits than the current emphasis on encouraging doctors to avoid prescribing drugs on “drugs-to-avoid” lists.

Comments

Patrice Villars said…
Very interesting post. In GNP school, we reviewed the meds to avoid in the elderly but not their actual relevance in a clinical setting. This is not to say that prescribing meds in the elderly is not both an art and a science, but you make an excellent point to again remember to look at the bigger picture.
ken covinsky said…
This is a really interesting way to think about this problem. This way of thinking about the problem makes a lot of clinical sense--and is more sound than just deeming meds good meds and bad meds. It is kind of interesting that while the approach you outline seems so obvious, there are few systematic approaches in place to do this type of monitoring. This is definitely an idea worth developing further. TP!
Alex Smith said…
Agree this is a more thoughtful approach to these issues than blacklisting medications. Relates well to Partrice's post about hospice care of geriatric patients. In end-of-life settings with older patients, I am concerned that there is not enough monitoring of the drugs that are prescribed in hospice and palliative care, and too many adverse side effects are ascribed to the "dying process."
Anonymous said…
This comment has been removed by a blog administrator.

Popular posts from this blog

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …

Opening the Black Box of LTACs: Podcast with Anil Makam

What happens in Long Term Acute Care Hospitals, or LTACs (pronounced L-tacs)?  I've never been in one.  I've sent patients to them - usually patients with long ICU stays, chronically critically ill, with a gastric feeding tube and a trach for ventilator support.  For those patients, the goals (usually as articulated by the family) are based on a hope for recovery of function and a return home.

And yet we learn some surprising things from Anil Makam, Assistant Professor of Medicine at UCSF.  In his JAGS study of about 14,000 patients admitted to LTACHs, the average patient spent two thirds of his or her remaining life in an institutional settings (including hospitals, LTACs and skilled nursing facilities).  One third died in an LTAC, never returning home.

So you would think with this population of older people with serious illness and a shorter prognosis than many cancers, we would have robust geriatrics and palliative care in LTACs?  Right? Wrong.

3% were seen by a geriatrici…

Length of Stay in Nursing Homes at the End of Life

One out of every four of us will die while residing in a nursing home. For most of us, that stay in a nursing home will be brief, although this may depend upon social and demographic variables like our gender, net worth, and marital status. These are the conclusions of an important new study published in JAGS by Kelly and colleagues (many of whom are geripal contributors, including Alex Smith and Ken Covinsky).

The study authors used data from the Health and Retirement Study (HRS) to describe the lengths of stay of older adults who resided in nursing homes at the end of life. What they found was that out of the 8,433 study participants who died between 1992 and 2006, 27.3% of resided in a nursing home prior to their death. Most of these patients (70%) actually died in the nursing home without being transferred to another setting like a hospital.

 The length of stay data were striking:

the median length of stay in a nursing home before death was 5 months the average length of stay was l…